AIM: To compare the efficacy between Ranibizumab and Conbercept for wet age-related macular degeneration.

METHODS: Totally 78 cases(78 eyes)of wet age-related macular degeneration treated in our hospital from February 2014 to March 2016 were selected and divided into Group A and Group B, each with 39 cases(39 eyes). Patients in two groups were given ranibizumab and conbercept respectively, and were followed up for 12mo. The various data including visual acuity, the macular foveal retinal thickness, choroidal neovascularization(CNV)leakage and complications were compares between two groups.

RESULTS: At 1wk, 1 and 3mo after treatment, the uncorrected vision of Group A was higher than that of Group B, the difference was statistical significance(t=14.05, 12.71, 18.27; P<0.05). The macular foveal retinal thickness at different time points in Group A was thinner than that of Group B, the difference held statistical meaning(t=13.04, 12.17, 18.19; P<0.05). Two groups' total efficiency at 1 and 3mo after operation had no statistical points(χ²=1.076, 0.253; P>0.05).

CONCLUSION: The ranibizumab and conbercept shows identical effect in treating CNV leakage of patients wet age-related macular degeneration without any serious complications occurred, but the comparison of the two shows that the improvements of visual acuity and macular foveal retinal thickness are better in ranibizumab treatment than in conbercept treatment.